A fourth mechanism has reached phase 3. Survodutide combines a GLP-1 receptor agonist with a glucagon receptor agonist, which is a different second lever from the GIP in tirzepatide or the amylin in the combination covered in the head-to-head that was finally run. Over 76 weeks, weight fell 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo [1].
The interesting number is not either headline. It is the gap between them. Stepping from 3.6 mg to 6.0 mg bought 0.8 percentage points of additional weight loss. Over that same step, gastrointestinal events rose from 80.9% to 89.7% of participants. Nearly nine in ten people on the higher dose reported a gastrointestinal event, for less than a point of extra result.
Two features of the design deserve attention. The placebo arm lost 5.4%, which is on the high side and narrows the real gap between drug and no drug to roughly seven points. And the primary analysis used a treatment-regimen estimand, which deliberately folds in early discontinuation, prohibited medication use and a prolonged escalation period rather than excluding them. That is the honest choice, and it produces smaller numbers than the efficacy-estimand figures quoted for other drugs.
At least 5% of body weight was lost by 72.6% of the 3.6 mg group, 71.9% of the 6.0 mg group and 46.3% of the placebo group. Note that the response rate is essentially identical across doses, reinforcing that the extra milligrams did not recruit more responders. No deaths were reported. The trial was funded by Boehringer Ingelheim, which the paper states.
For a reader tracking what is coming, this is a drug worth watching and a result worth reading carefully. Thirteen percent at 76 weeks does not reach the figures in the pooled weight-loss averages for the drugs already approved, and the tolerability at the top dose is heavy. Whether the glucagon arm earns its place will depend on outcomes nobody has measured yet, not on the weight column — the same caution that applies to everything in the not-for-sale pipeline.